Trial Profile
A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2020
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms GeparTREIZE
- 30 Apr 2020 This trial has been completed in Germany according to European Clinical Trials Database record.
- 09 Apr 2019 New trial record